Publications

What are the pricing and market access launch challenges facing companies today? The results of our survey are in!

Over the last 3 months, we have been conducting a survey to understand pricing and market access launch drivers and challenges for a successful PMA launch, and the areas that can be improved for future launches. We are delighted to say that we have received fabulous feedback, with responses from at least 15 industry executives across global pharma companies.

Key findings include:

  • Internal company barriers (e.g. budget/personnel) are rarely considered a significant challenge by pricing and market access teams.
  • Pricing and market access teams now form a core part of the Commercial launch team and are considered a ‘strategic partner’ in 31% of cases.
  • Most recent pricing and market access launches faced evidence challenges during payer negotiations, such as endpoint and comparator selection, and patient subpopulation data.
  • Pricing and market access teams must be involved earlier in the clinical development process to ensure that the necessary clinical and economic evidence is […]
By |2019-09-06T13:16:56+01:00September 5th, 2019|News, Publications|0 Comments

Is the new NICE appraisal process for oncology indications too positive in its assessment of cancer drugs in England?

Since 29 July 2016, the NICE appraisal process for oncology indications in England has been modified to allow one of three outcomes; recommended for routine use, not recommended, or recommended within the Cancer Drugs Fund (CDF) managed access scheme. This study investigates the outcomes of NICE appraisals for new cancer drugs assessed via the modified process.

Read our findings here…… (Is the new NICE appraisal process too positive?)

By |2018-10-19T15:05:25+01:00October 19th, 2018|Publications|0 Comments

ICERS are not all the same. How cost-effectiveness estimates differ between the UK and US

Is there is a difference between incremental cost-effectiveness ratios (ICERs) in oncology calculated by the Institute for Clinical and Economic Review (ICER) in the US and the National Institute for Health and Care Excellence (NICE) in the UK, and if so, are any differences are solely driven by drug costs.

Read our findings here ICERS are not all the same. How cost-effectiveness estimates differ between the UK and US

By |2018-06-08T12:34:52+01:00May 28th, 2018|Publications|0 Comments

What impact does NICE’s modified Cancer Drugs Fund process mean for patient access to new oncology pharmaceuticals in England?

Remap Consulting recent analysis: “What impact does NICE’s modified Cancer Drugs Fund process mean for patient access to new oncology pharmaceuticals in England?” was presented at ISPOR’s 20th Annual European Congress in Glasgow.

In April 2016, NICE modified the Cancer Drugs Fund (CDF) appraisal process in England, to review all new oncology indications and publish final guidance within 90 days of marketing authorisation. Additionally, 14 existing legacy indications from the previous CDF had not undergone a NICE assessment and required review.

The new CDF has a fixed budget of £340m and treatments appraised under this process may; be recommended for routine use by NHS England; be retained in the CDF to gather additional evidence; not be recommended. In some cases, positive recommendations may be subject to confidential patient access schemes or restricted to specific patient populations.

This study investigates NICE evaluations of new cancer indications and of legacy CDF indications […]

By |2018-06-08T09:41:12+01:00November 13th, 2017|News, Publications|0 Comments